Science News
from research organizations

Potential Drug For Liver Carcinoma

Date:
May 22, 2009
Source:
World Journal of Gastroenterology
Summary:
A research group in China investigated the anti-tumor effects of a chrysin derivative, 5-allyl-7-gen-difluoromethylenechrysin (ADFMChR), on human liver carcinoma HepG2 cell line. Their results showed that ADFMChR can induce apoptosis of HepG2 cells in vitro and demonstrated its molecular mechanism, thereby providing a new idea for research about pharmaceutical prevention and cure of human liver cancer.
Share:
       
FULL STORY

Looking for efficient anti-tumor drugs is a hot research area. Chrysin (5,7-dihydroxy flavone), a natural widely-distributed flavonoid, has been reported to have many different biological activities such as anti-oxidant, anti-virus, antidiabetogenic activity and clear anxiolytic effect. However, Chrysin is limited in its clinical application because of its modest absorption in the intestine and rapid in vivo glycosylation. To improve the biological activity of chrysin, a number of its derivatives have been prepared for biological testing. 5-allyl-7-gen-difluoromethylenechrysin (ADFMChR) is one of them.

A research team led by Dr. Jian-Guo Cao from China investigate the anti-tumor effect of ADFMChR in vitro. 

In their study, HepG2 cells and L-02 cells were cultured and the inhibitory effect of ADFMChR on their proliferation was measured by MTT assay. The apoptosis of HepG2 cells was determined by flow cytometry using propidium iodide fluorescence staining. The influence of ADFMChR on the proxisome proliferator-activated receptor γ (PPARγ), NF-κB, Bcl-2 and Bax protein expression of HepG2 cells were analyzed by Western blotting.

They found that ADFMChR significantly inhibited the proliferation of HepG2 cells in a dose-dependent manner, with little effect on growth of L-02 cells. Western blotting analysis revealed that after 24 h of treatment with 3.0, 10.0, 30.0 μmol/L ADFMChR, PPARγ and Bax protein expression increased but Bcl-2 and NF-κB expression decreased in HepG2 cells; however, pre-incubation with 10.0 μmol/L GW9662, a blocker of PPARγ, could efficiently antagonize and weaken the regulatory effect of 3.0, 30.0 μmol/L ADFMChR on PPARγ and NF-κB protein expression in HepG2 cells.

This finding may provide a molecular basis for the clinically observed cancer-preventive effects of ADFMChR and new clues for research about pharmaceutical prevention and cure of human liver carcinoma.


Story Source:

The above post is reprinted from materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Tan XW, Xia H, Xu JH, Cao JG. Induction of apoptosis in human liver carcinoma HepG2 cell line by 5-allyl-7-gendifluoromethylenechrysin. World J Gastroenterol, 15(18): 2234-2239

Cite This Page:

World Journal of Gastroenterology. "Potential Drug For Liver Carcinoma." ScienceDaily. ScienceDaily, 22 May 2009. <www.sciencedaily.com/releases/2009/05/090522101842.htm>.
World Journal of Gastroenterology. (2009, May 22). Potential Drug For Liver Carcinoma. ScienceDaily. Retrieved July 30, 2015 from www.sciencedaily.com/releases/2009/05/090522101842.htm
World Journal of Gastroenterology. "Potential Drug For Liver Carcinoma." ScienceDaily. www.sciencedaily.com/releases/2009/05/090522101842.htm (accessed July 30, 2015).

Share This Page: